Eupraxia Pharmaceuticals Inc. (EPRX.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
2067 Cadboro Bay Road
Victoria, BC V8R 5G4
Canada
Phone
250-590-3968
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
March 09, 2021
| Name | Title | Pay | Year Born |
| James A. Helliwell FRCPC | Chief Executive Officer & Director | 954,736 | 1974 |
| Amanda Malone | Chief Scientific Officer & Chief Operating Officer | 468,212 | 1981 |
| Paul Anthony Brennan | Chief Corporate Development Officer | 513,614 | N/A |
| Alexander John Rothwell | Chief Financial Officer | 581,586 | 1969 |
| Mark Kowalski | Chief Medical Officer | 790,957 | 1955 |
| Jeymi Tambiah | Chief Medical Officer | 790,957 | N/A |
| Alex Therien | Executive VP of R&D | 0 | N/A |
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.